Peptide Therapeutics Market Report - Size & Share 2027

Peptide Therapeutics Market Forecast to 2027 - Global Analysis By Type (Generic and Innovative); Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, and Others); Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid Technology); Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, and Pain, Dermatology), and Geography

Publication Month : Feb 2021

  • Report Code : TIPRE00003793
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 198
Inquire Before Buy

PRICING

$4550

$2730

[Research Report] The peptide therapeutics market size is expected to grow to US$ 50,003.15 million by 2027 from US$ 26,998.21 million in 2020; the peptide therapeutics market is estimated to grow with a CAGR of 9.2% from 2020-2027.

Analyst Perspective

The peptide therapeutics market is likely to grow due to the increasing emphasis on developing novel peptide therapies and the potential of peptides for regenerative medicine. In addition, the market is likely to have a positive impact due to the growing extensive product pipeline and robust research and development for peptide therapeutics. Moreover, the significantly growing incidences of cancer, diabetes, and respiratory diseases are leading to the growing demand for peptide therapeutics. Furthermore, the companies operating in the market are significantly involved in aggressive research and development and are focusing on expanding their customer base in developing regions. For instance, in May 2023, SynCrest Inc. launched CRDMO service for peptide-based therapeutics through a joint venture of Otsuka Chemical Co., Ltd. and Yokogawa Electric Corporation. The service will be provided to pharmaceutical companies and research institutions in Japan, Europe, North America, and South America. Such strategic decisions are also enabling market growth during 2020–2027.

Market Overview

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. Extensive efforts have been made in pharmaceutical research and development (R&D) to innovate new peptides for treating chronic conditions. Over 7000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions such as neurotransmitters, hormones, ion channel ligands, and growth factors. The growth of the peptide therapeutics market is attributed to a few key factors, such as growing investments in peptide therapeutics and the increasing prevalence of chronic disorders and infectious diseases across the world are expected to boost the market growth. However, operational limitations of peptides are anticipated to deter market growth. The global peptide therapeutics market is segmented into type, route of administration, synthesis technology, and application. Based on geography, the global peptide therapeutics market is classified as North America, Europe, Asia Pacific, Middle East &, and South & Central America.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Peptide Therapeutics Market: Strategic Insights

peptide-therapeutics-market
Market Size Value inUS$ 26,998.21 Million in 2020
Market Size Value byUS$ 50,003.15 Million by 2027
Growth rateCAGR of 9.2% from 2020 to 2027
Forecast Period2020-2027
Base Year2020
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Market Driver

Growing Investments on Peptide Therapeutics

Continuous R&D activities in peptide therapeutics have discovered its benefits in tackling a range of chronic disorders, such as renal disorders, genetic conditions, oncology, and neurodegenerative conditions. The effectiveness of the outcomes of peptide therapies is generating investments in the development of new drugs. For instance, in December 2020, Peptilogics received funding of around US$ 35.4 million through the rounds of series funding. The funding would accelerate the development of its peptide therapeutics pipeline candidate, PLG0206. Moreover, in October 2020, Lassogen raised US$ 4.5 million through the rounds of series funding for the development of lasso peptides. According to the company, the peptide is expected to offer superior treatment outcomes for cancer, autoimmunity, pain, and inflammation. Further, in December 2020, ONL Therapeutics closed rounds of series funding (US$ 46.9 million) for its ONL1204 peptide candidate for retinal diseases.

The companies are also focusing on extended investments to expand their operations in the peptide market. For instance, in March 2019, Creative Peptides, a US-based company launched its new pharmaceutical peptides services with an aim to extend the applications of peptides for drug discovery. Moreover, in October 2019, UCB announced its plan to acquire RA Pharmaceuticals to increase its peptide drug portfolio. At present, RA Pharmaceutical has its product in pipeline. Such investments are expected to accelerate the growth of the peptide therapeutics market during the forecast period.

Segment Analysis

The global peptide therapeutics market is segmented on the basis of type, route of administration, synthesis technology, and application. Based on the type, the market is segmented into generic and innovative. The innovative segment held the largest market share of the market in 2020. Novel peptide drugs given to patients to treat specific disease is referred to as innovative peptide drugs. These innovative drugs help in offering better results to patients for treating diseases than the drugs available in the market. The pharmaceutical company invests a high amount of money in developing such novel pharmaceutical products. The company receives patent approval for its drug, and no other company can produce the drug, and it belongs exclusively to the company. Growing approval of peptide drugs is likely to favor market growth.  Between 2015 and 2019, the US Food Drug Administration (FDA) approved a total of 208 new drugs (150 new chemical entities and 58 biologics), of which 15 were peptides or peptide-containing molecules, and it accounts for 7% of the total number of drugs. For instance, Novo Nordisk’s Ozempic (semaglutide) received U.S. Food and Drug Administration (FDA) approval in January 2020 to reduce the risk of cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes. Thus, such instances are leveraging the growth of the segment. However, the generic segment is anticipated to register the highest CAGR in the market during 2020–2027.

Based on the route of administration, the market is segmented into parenteral, oral, mucosal, pulmonary, and others. The parenteral segment held the largest market share in 2020, and the oral segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on the synthesis technology, the market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), hybrid technology. The solid phase peptide synthesis segment held the largest market share in 2020, and hybrid technology segment is anticipated to register the highest CAGR in the market during 2020–2027.

Based on application, the peptide therapeutics market is segmented into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest market share of the market in 2020. However, the metabolic disorder segment is estimated to register the highest CAGR in the market during the period.

Regional Analysis

North America held the largest market share of the global peptide therapeutics market, valued at US$ 10,869.48 million in 2020 and estimated to grow at a CAGR of 9.4% from 2020–2027. The North American peptide therapeutics market is divided into the US, Canada, and Mexico. The US held the largest share of the North American peptide therapeutics market in 2019. Growing awareness regarding peptide-based drugs, increasing investments for drug discovery, and rising demand for alternative therapies for chronic disease management are anticipated to drive the growth of US peptide therapeutics market during the forecast period.

In Canada, the market is expected to grow owing to the development of the healthcare systems and the rapidly increasing adoption of modern cell related technologies. On the other hand, Mexico is likely to experience market growth opportunities due to increasing awareness of the benefits offered by peptide therapeutics and increasing investments by the government. However, the Asia Pacific is estimated to be the fastest-growing region owing to the factors such as the increasing need for superior treatment solutions, favorable regulatory scenarios, increasing focus on research and development activities, and growing awareness regarding the benefits offered by peptide therapies. Additionally, developing healthcare infrastructure and increasing investments in order to boost research activities are projected to drive the Asia Pacific peptide therapeutics market during the forecast period.

Key Player Analysis

The peptide therapeutics market majorly consists of the players such as Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and Glaxosmithkline PLC, amongst others. The two leading players in the market are Eli Lilly and Company and Amgen Inc. These companies are involved in various organic and inorganic developments that have paved the way for significant growth opportunities.

Recent Developments

Companies in the peptide therapeutics market highly adopt inorganic and organic strategies. A few recent key market developments are listed below: 

  • In November 2020, Novo Nordisk has developed Rybelsus using Emisphere’s Eligen SNAC drug delivery technology. Novo Nordisk has acquired Emisphere which allows the former company to gain control over the Eligen platform and to eliminate future royalty obligations to the latter company.
  • In February 2020, BioMotiv and Bristol-Myers Squibb Company (NYSE: BMY) today announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases. Under the terms of the partnership, Bristol-Myers Squibb will contribute the IP, data, and reagents for a series of small molecules against an undisclosed mechanism, and BioMotiv, through the formation of Anteros Pharmaceuticals, working in close partnership with Yale, will be solely responsible for research and development. Once Anteros nominates a pre-clinical candidate, Bristol-Myers Squibb has the option to acquire the company from BioMotiv under pre-agreed terms.
  • In December 2020, Eli Lilly and Company announced the results of its tirzepatide drug candidate for the management of type-2 diabetes. According to the results, the product has shown its efficacy in reducing A1C and body weight in type-2 diabetic patients.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, and Application

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


Who are the major players in the peptide therapeutics market?

The peptide therapeutics market majorly consists of the players such as Eli Lilly and Company, Amgen Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Polypeptide Group, EVER Pharma GmbH, Bristol-Myers Squibb Company, Novo Nordisk A/S, Sanofi, AstraZeneca PLC, and Glaxosmithkline PLC amongst others.

What are peptide therapeutics?

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. There are extensive efforts have been taken in pharmaceutical research and development (R&D) to innovate new peptides for the treatment of chronic conditions. Over 7000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors, amongst others.

What are the driving factors for the peptide therapeutics market across the globe?

The growth of the market is attributed to some key driving factors such as growing investments on peptide therapeutics and increasing prevalence of metabolic and infectious diseases.

The List of Companies - Peptide Therapeutics Market

  1. Eli Lilly and Company
  2. Amgen Inc.
  3. TEVA PHARMACEUTICAL INDUSTRIES LTD
  4. Polypeptide Group
  5. EVER Pharma GmbH
  6. Bristol-Myers Squibb Company
  7. Novo Nordisk A/S
  8. Sanofi
  9. AstraZeneca PLC
  10. Glaxosmithkline PLC  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Peptide Therapeutics Market